close

News

LATEST POSTS from News

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics Agilent Technologies will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for…..

Evotec – Secarna: new partnership in antisense oligonucleotide-based therapeutics

Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and  Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO,  combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..

Trend Chart On Innovative Bioindustries – July 2020, 29th

Trend Chart On Innovative Bioindustries - July 2020, 29th FEATURE STORY GSK and CureVac announce strategic mRNA technology collaboration GSK and CureVac announced on July 20th the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies targeting…..

Trend Chart On Innovative Bioindustries – June 2020, 23rd

Trend Chart On Innovative Bioindustries - June 2020, 23rd FEATURE STORY ● Draft landscape of COVID-19 candidate vaccines This landscape document (published on June 16th) has been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product…..

A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies

A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies Orgenesis, a global US biotech company developing personalized therapies and closed processing systems through its Cell & Gene Therapy (CGT) Biotech Platform, announced a research and development collaboration with Hospital Infantil…..